

MO HEALTHNET DRUG UTILIZATION REVIEW BOARD

October 16, 2019

Missouri Coalition for Community Behavioral Healthcare, 221 Metro Dr., Lower Level CEO Room, Jefferson City MO

DUR BOARD MEMBERS PRESENT

Susan Abdel-Rahman Pharm D, Board Chair
Kenneth Haller, MD
Charlene Heyde, RPh
Stacy Mangum, Pharm D
Glen Talboy, MD

DUR BOARD MEMBERS ABSENT

Ginger Nicole, MD, CEDS
Sandra Bollinger, Pharm D
Jennifer Passanise, FNP

OTHERS IN ATTENDANCE

| | |
|--------------------------|-----------------------------|
| Audrey Rattan, Alkermes | Jim Bauman, Pfizer |
| Rob Kilo, Biogen | Dann Piplen, Sarepta |
| Brian Strickland, Gilead | Leslie Zaneth, Sarepta |
| Erica Brumleve, GSK | Melissa Edenfield, Sunovion |

MHD STAFF PRESENT

Mark Roaseau, R.Ph, Clinical Pharmacist
Joshua Moore, Director of Pharmacy
Angela Wilson, Pharmacy Operations Manager
Franki Moseley, Administrative Office Support Assistant
Elizabeth Sissom, RN, Clinical Management
Desiree Vitale, Legal Counsel
Elizabeth Short, Program Specialist
Dr. Timothy Kling, MD, Assistant Medical Director
Jackie Hickman, Program Manager
Connie Sutter, Fiscal Manager
Keri Ballew, Drug Rebate Unit Medicaid Specialist

CONTRACTED STAFF PRESENT

Olivia Rush, Conduent
Jennifer Colozza,, Conduent
Crystal Wickers, Conduent
Katie Wilbers, Pharm D, Conduent
Luke Boehmer, Pharm D, Conduent
Megan Fast, Conduent
Valerie Schmitz, Wipro
Chelsea Pendleton, Wipro
Geri Roling, Wipro

Drug Utilization Review Board Minutes October 16, 2019

Alexander Gresham, KUSOP
 Tom Guyer, Lilly
 Meghan Kerrigan, Merck
 Evie Knisely, Novartis
 Don Kempen, Novo Nordisk
 Rick Kegler, Otsuka

Peter Rossman, United Therapeutics

| | |
|---|--|
| Welcome, Introductions and Opening Remarks | Susan Abdel-Rahman, called the meeting to order. Joshua Moore, the new MHD Director of Pharmacy, facilitated the meeting on behalf of the MO HealthNet Division (MHD). Introductions were made all around. |
| Minutes Review and Approval | Minutes of the July 2019 DUR Board meeting were reviewed and approved as submitted. (See Roll Call Votes) |
| Multiple Sclerosis | <ul style="list-style-type: none"> • Discussion – Joshua Moore presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes). |
| Pharmacy Program/Budget Update | Elizabeth Short, Program Specialist, presented a brief power point presentation. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking and State Opioid activities. |
| Old Business Implementation Schedule | Joshua Moore discussed the Proposed Implementation Schedule for Edits, including PDL classes being presented for annual review, which was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included PDL decisions to be implemented January 2020. Pending ratification, PDL decisions from September/October will be implemented January 2020. Schedules may be found on the MHD web page at https://dss.mo.gov/mhd/cs/pharmacy/pdf/impsched.pdf |
| New Drug Review | <p>Joshua Moore reviewed the new drug products identified for the quarter April, May, and June 2019 and the recommended status within the clinical program.</p> <ul style="list-style-type: none"> • Discussion - A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet, along with the Drug Prior Authorization Committee's actions/decisions. This listing was also provided to all attending. |

| Clinical Edits | |
|--|---|
| BiDil Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| Botulinum Toxin Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| Diacomit Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| Duchenne Muscular Dystrophy (DMD) Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| Emsam Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| Lambert-Eaton Myasthenic Syndrome(LEMS) Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |

| | |
|--|---|
| Narcolepsy Inhibitors Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| Oxandrin Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| Psychotropic Medications Polypharmacy Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| Ranexa Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| SNRI Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| SSRI Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| Synagis Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |

| | |
|--|---|
| Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| Zolgensma Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| Zometa Clinical Edit | <ul style="list-style-type: none"> • Discussion – Joshua Moore reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| Preferred Drug List ((PDL) Annual Review | |
| ACE Inhibitors/Calcium Channel Blocker Combination Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| ACE Inhibitors and ACE Inhibitors Diuretic Combination Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| ADHD – Amphetamines – Short Acting Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| ADHD – Methylphenidate – Long Acting Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| ADHD – Methylphenidate – Short Acting Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |

| | |
|--|---|
| ADHD – Amphetamines – Long Acting Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| ADHD – Non-stimulant Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| ARB and ARB Diuretic Combination Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Angiotensin II Receptor/Calcium Channel Blocker Combination Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Anticoagulant Agents: Oral and Subcutaneous | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Antiplatelet Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Beta Adrenergic Blocker and Beta Adrenergic Blocker Diuretic Combination Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Calcium Channel Blocker Agents (Dihydropyridines) | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Calcium Channel Blocker Agents (Non-Dihydropyridines) | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Direct Renin Inhibitors and Direct Renin Inhibitors Combination Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |

| | |
|--|---|
| Dry Eye Disease Agents - NEW | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Lipotropic Agents: Homozygous Familial Hypercholesterolemia Products | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Lipotropic Agents: Niacin Derivatives | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Lipotropic Agents: Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Lipotropic Agents: Statins (HMG Co-A Reductase Inhibitors) and Statin Combination Products | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Lipotropic Agents: Triglyceride Lowering Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Proton Pump Inhibitor Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Pulmonary Arterial Hypertension (PHA) Agents: Inhaled/Injectable | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Pulmonary Arterial Hypertension (PHA) Agents: Oral Endothelin Receptor Antagonists (ETRAAs) | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |

| | |
|---|---|
| Pulmonary Arterial Hypertension (PHA) Agents: Oral Phosphodiesterase-5 (PDE5) Inhibitors and Soluble Guanylate Cyclase (SCG) Stimulators | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Pulmonary Arterial Hypertension (PHA) Agents: Oral Prostacyclin Pathway Agonists | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |
| Sympatholytic Antihypertensive Agents | <ul style="list-style-type: none"> • Discussion – Joshua Moore, presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes) |

| | |
|--|--|
| Call Center Statistics Clinical Edit Summary Report | A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were also provided. Dr. Luke Boehmer also presented updated Call Center Statistics. |
| Conduent Update | Dr. Luke Boehmer discussed the Call Center Statistics for the Short Acting Single Agent Opioids, Short Acting Combination Opioids, and Long Acting Opioids both Pre-Implementation of the last dosing reductions and Post-implementation of the last dosage reductions. Dr. Boehmer discussed the Spend PMPM and Claims PMPM for the Short Acting Single Agent Opioids, Short Acting Combination Opioids, and Long Acting Opioids. |
| Drug Utilization Review Activities | Dr. Katie Wilbers presented the Migraine Outcomes, Naloxone Management Intervention, Anticonvulsant Drug Use Evaluation, and Diabetes Disease Management documents. |
| Preferred Drug List Announcement | A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page: http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf |

| | |
|--|--|
| Program Utilization: Top 25 Drugs Summary | Luke Boehmer, Pharm D, reviewed the Top 25 Drugs Summary Reports for the 1st, 2 nd , 3 rd , & 4th quarter 2019. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims. |
| Adjourn | Dr. Kenneth Haller, made a motion to move to close the meeting under Section 610.021 (5),(14) to go into Executive Session for the sole purpose of discussing individual participant specific medical information. (See attached roll call vote). At the conclusion of this discussion the meeting was adjourned so that the Executive Session could start. Separate minutes are created for this session. (See attached roll call vote). The next DUR Board meeting is scheduled for January 15, 2020, at the Missouri Coalition for Community Behavioral Healthcare, Lower Level CEO Room, 221 Metro Drive , Jefferson City MO. |

Roll Call Votes – October 16, 2019

Roll Call for DUR 10/16/2019

| MEMBER | MEETING MINUTES | Multiple Schlerosis PDL | Clinical Edits | ALL RECOMMENDATIONS BLOCK VOTE-PDL's | CLOSE SESSION PURSUANT TO SECTION 610.021 Subsection (14), (5) | ADJOURN |
|--------------------|------------------------|--------------------------------|-----------------------|---|---|----------------|
| Susan Abdel-Rahman | Y | Y | Y | Y | Y | Y |
| Charlene Heyde | Y | S | Y | S | Y | Y |
| Sandra Bollinger | Absent | | | | | |
| Kenneth Haller | Y | Y | Y | M | M | M |
| Glenn Talboy | S | M | S | Y | Y | Y |
| Jennifer Passanise | Absent | | | | | |
| Stacy Mangum | M | Y | M | Y | S | S |

| | | | | | | |
|--------------|--------|--|--|--|--|--|
| Ginger Nicol | Absent | | | | | |
|--------------|--------|--|--|--|--|--|

A-Absent

M-Motion

S-Second the Motion

Y-yes for the vote

Needs a Conference

Line in case he
cannot be there in
person

M - motion to vote

S - second to vote

Y - yes to the vote

N – no to the vote

A - absent

DUR BOARD MEMBERS PRESENT

Susan Abdel-Rahman, Pharm D – Board Chair

Charlene Heyde, RPh

Sandra Bollinger, Pharm D

Glenn Talboy, MD

Stacy Mangum, Pharm D

Ginger Nicol, MD, CEDS

DUR BOARD MEMBER GUESTS

Nick Legrand, STLCOP Student

Chelsea Clark, STLCOP Student

DUR BOARD MEMBERS ABSENT

Jennifer Passanise, FNP

Kenneth Haller, MD

Randy Beckner, Pharm D

MHD STAFF PRESENT

Mark Roaseau, RPh, Clinical Pharmacist

Frances (Franki) Moseley, Administrative Office Support Assistant

Elizabeth Short, Medicaid Specialist

Jenna McTeer, RN, Clinical Management

Lisa Smith, Program Development Specialist

Mitch Ruth, Fiscal Unit Manager

CONTRACTED STAFF PRESENT

Joshua Moore, Pharm D, Conduent

Katie Wilbers, Pharm D, Conduent

Luke Boehmer, Pharm D, Conduent

Janelle Sheen, Pharm D, Conduent

Richard Pope, Pharm D, Magellan

EXECUTIVE SESSION

October 18, 2017

| | |
|----------------|---|
| Minutes Review | There were no July minutes for the Executive Session to be approved as submitted. |
| Case Reviews | One Case for Review-Separate Minutes are prepared for this review. |
| Adjourn | Executive session |